Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence

Oncogene

Volumn 29, Issue 30, 2010, Pages 4261-4275

  Suraneni, M V ^a   Schneider Broussard, R ^a   Moore, J R ^a   Davis, T C ^a   Maldonado, C J ^a   Li, H ^a   Newman, R A ^b   Kusewitt, D ^a   Hu, J ^b   Yang, P ^b   Tang, D G ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

15 lipoxygenase 2; hyperplasia; prostate; senescence; stem cells; tumor suppression

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE 2; COMPLEMENTARY DNA; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL AGING; FEMALE; GENE EXPRESSION REGULATION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SENESCENCE; STEM CELL; TRANSGENIC MOUSE;

ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; CELL AGING; CELL PROLIFERATION; GENE EXPRESSION PROFILING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MALE; MICE; MICE, TRANSGENIC; PROSTATE; PROSTATIC HYPERPLASIA;

MUS; MUS MUSCULUS;

EID: 77955176918     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.197     Document Type: Article

References (54)

1. Abate-Shen C, Shen MM. (2000). Molecular genetics of prostate cancer. Genes Dev 14: 2410-2434.
2. Allred DC, Harvey JM, Berardo M, Clark GM. (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168.
3. Bhatia B, Jiang M, Suraneni M, Patrawala L, Badeaux M, Schneider-Broussard R et al. (2008). Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells. J Biol Chem 283: 27957-27972.
4. Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, Chopra D et al. (2003). Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 278: 25091-25100.
5. Bhatia B, Tang S, Yang P, Doll A, Aumueller G, Newman RA et al. (2005). Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells. Oncogene 24: 3583-3595.
6. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B et al. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665.
7. Brash AR, Boeglin WE, Chang MS. (1997). Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA 94: 6148-6152.
8. Chano T, Ikegawa S, Kontani K, Okabe H, Baldini N, Saeki Y. (2002). Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene 21: 1295-1298.
9. Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH et al. (2003). 15-hydroxy-eicosatetraenoic acid arrests growth of color-ectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. Int J Cancer 107: 837-843.
10. Chen X, Schneider-Broussard R, Hollowell D, McArthur M, Jeter C, Benavides F et al. (2009). Abnormal differentiation, hyperplasia and embryonic/perinatal lethality in BK5-T/t transgenic mice. Differentiation 77: 324-334.
11. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
12. Dillner K, Kindblom J, Flores-Morales A, Shao R, Tornell J, Norstedt G et al. (2003). Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 144: 4955-4966.
13. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R et al. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238.
14. Fang H, Harris SC, Su Z, Chen M, Qian F, Shi L et al. (2009). ArrayTrack: an FDA and public genomic tool. Methods Mol Biol 563: 379-398.
15. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. (2008). Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 105: 20882-20887.
16. Gonzalez AL, Roberts RL, Massion PP, Olson SJ, Shyr Y, Shappell SB. (2004). 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. Hum Pathol 35: 840-849.
17. Ibaragi S, Yoshioka N, Kishikawa H, Hu JK, Sadow PM, Li M et al. (2009). Angiogenin-stimulated rRNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia. Mol Cancer Res 7: 415-424.
18. Ikebuchi K, Chano T, Ochi Y, Tameno H, Shimada T, Hisa Y et al. (2009). RB1CC1 activates the promoter and expression of RB1 in human cancer. Int J Cancer 125: 861-867.
19. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith Jr JA et al. (2000). Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31: 1146-1154.
20. Jiang WG, Watkins G, Douglas-Jones A, Mansel RE. (2006). Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 74: 235-245.
21. Jisaka M, Kim RB, Boeglin WE, Brash AR. (2000). Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. J Biol Chem 275: 1287-1293.
22. Jisaka M, Kim RB, Boeglin WE, Nanney LB, Brash AR. (1997). Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin. J Biol Chem 272: 24410-24416.
23. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS et al. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 78: i-xv.
24. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L. (2005). Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 11: 8358-8363.
25. Kelavkar UP, Parwani AV, Shappell SB, Martin WD. (2006). Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. Neoplasia 8: 510-522.
26. Kilty I, Logan A, Vickers PJ. (1999). Differential characteristics of human 15-lipoxygenase isozymes and a novel splice variant of 15S-lipoxygenase. Eur J Biochem 266: 83-93.
27. Kim E, Rundhaug JE, Benavides F, Yang P, Newman RA, Fischer SM. (2005). An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis. Oncogene 24: 1174-1187.
28. Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J et al. (2003). Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144: 2269-2278.
29. Lawson DA, Witte ON. (2007). Stem cells in prostate cancer initiation and progression. J Clin Invest 117: 2044-2050.
30. Mahipal SV, Subhashini J, Reddy MC, Reddy MM, Anilkumar K, Roy KR et al. (2007). Effect of 15-lipoxygenase metabolites, 15-(S)-HPETE and 15-(S)-HETE on chronic myelogenous leukemia cell line K-562: reactive oxygen species (ROS) mediate caspase-dependent apoptosis. Biochem Pharmacol 74: 202-214.
31. Majumder PK, Grisanzio C, OConnell F, Barry M, Brito JM, Xu Q et al. (2008). A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14: 146-155.
32. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q et al. (2003). Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 100: 7841-7846.
33. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S et al. (2001). A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 61: 2239-2249.
34. Melkoumian ZK, Peng X, Gan B, Wu X, Guan JL. (2005). Mechanism of cell cycle regulation by FIP200 in human breast cancer cells. Cancer Res 65: 6676-6684.
35. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science 322: 949-953.
36. Schweiger D, Furstenberger G, Krieg P. (2007). Inducible expression of 15-lipoxygenase-2 and 8-lipoxygenase inhibits cell growth via common signaling pathways. J Lipid Res 48: 553-564.
37. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. (1999). 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155: 235-245.
38. Shappell SB, Keeney DS, Zhang J, Page R, Olson SJ, Brash AR. (2001). 15-Lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. J Invest Dermatol 117: 36-43.
39. Shappell SB, Olson SJ, Hannah SE, Manning S, Roberts RL, Masumori N. (2003). Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 63: 2256-2267.
40. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA et al. (2004). Prostate pathology of genetically engineered mice: definitions and classification. the consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res 64: 2270-2305.
41. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L et al. (2000). p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157: 1769-1775.
42. Spindler SA, Sarkar FH, Sakr WA, Blackburn ML, Bull AW, LaGattuta M et al. (1997). Production of 13-hydroxyoctadecadie-noic acid (13-HODE) by prostate tumors and cell lines. Biochem Biophys Res Commun 239: 775-781.
43. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL et al. (2006). 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25: 6015-6025.
44. Sugimura Y, Cunha GR, Donjacour AA. (1986). Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 34: 961-971.
45. Tang DG, Bhatia B, Tang S, Schneider-Broussard R. (2007a). 15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 82: 135-146.
46. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R et al. (2007b). Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 46: 1-14.
47. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J et al. (2002). Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 277: 16189-16201.
48. Tang Y, Wang MT, Chen Y, Yang D, Che M, Honn KV et al. (2009). Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer. Int J Cancer 124: 1545-1551.
49. Tran CP, Lin C, Yamashiro J, Reiter RE. (2002). Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1: 113-121.
50. Wang D, Chen S, Feng Y, Yang Q, Campbell BH, Tang X et al. (2006). Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. Tumour Biol 27: 261-273.
51. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV et al. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.
52. Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V et al. (2003). Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 5: 121-127.
53. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF. (2006). A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 103: 14519-14524.
54. Zhang J, Thomas TZ, Kasper S, Matusik RJ. (2000). A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorti-coids in vitro and in vivo. Endocrinology 141: 4698-4710.